

## Cover Figure

Artistic impression of a red blood cell - created by somersault18:24 ([www.somersault1824.com](http://www.somersault1824.com)).

## Hematology News

- 1 **'Selectin' endothelium to protect blood stem cells**  
*Noemi A. Zambetti and Marc H.G.P. Raaijmakers*

## Editorials and Perspectives

- 2 **Quality of Life in hematology: European Hematology Association theme of the year ... and years to come**  
*Christine Chomienne, Margarita Guenova, Anton Hagenbeek, Catherine Lacombe, Shaun McCann, Sam Salek, Jan Geissler, Ineke van der Beek*
- 4 **Can an art intervention influence quality of life in a hospitalized patient?**  
*Shaun R. McCann*
- 7 **Using patient-reported health status to improve prognostic assessment in patients with acute myeloid leukemia: current challenges and future applications**  
*Fabio Efficace, Francesco Lo-Coco*

## Review Articles

- 10 **Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?**  
*Stephanie Beurlet, Christine Chomienne, and Rose Ann Padua*

## Articles

### Stem Cell Transplantation

- 23 **Rabbit antithymocyte globulin (Thymoglobulin®) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients**  
*Il-Kang Na, Friedrich Wittenbecher, Mikalai Dziubianau, Anne Herholz, Angela Mensen, Désirée Kunkel, Olga Blau, Igor Blau, Eckhard Thiel, Lutz Uharek, Carmen Scheibenbogen, Kathrin Rieger, and Andreas Thiel*

### Graft-Versus-Host Disease

- 31 **Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells**  
*Anne-Kathrin Hechinger, Kristina Maas, Christoph Dürr, Franziska Leonhardt, Gabriele Prinz, Reinhard Marks, Ulrike Gerlach, Maike Hofmann, Paul Fisch, Jürgen Finke, Hanspeter Pircher, and Robert Zeiser*
- 41 **Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease**  
*Masahiro Hirayama, Eiichi Azuma, Atsuko Nakagawa-Nakazawa, Tadashi Kumamoto, Shotaro Iwamoto, Keishiro Amano, Shigehisa Tamaki, Eiji Usui, and Yoshihiro Komada*

### Non-Hodgkin's Lymphomas

- 50 **ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study**  
*Ilse Oschlies, Jasmin Lisfeld, Laurence Lamant, Atsuko Nakazawa, Emanuele S. G. d'Amore, Ulrika Hansson, Konnie Hebeda, Ingrid Simonitsch-Klupp, Jadwiga Maldyk, Leonhard Müllauer, Marianne Tinguely, Markus Stücker, Marie-Cecile LeDeley, Reiner Siebert, Alfred Reiter, Laurence Brugières, Wolfram Klapper, and Wilhelm Woessmann*



Official Organ of the  
European Hematology Association

57

**Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas**

*Esperanza Martín-Sánchez, Socorro M. Rodríguez-Pinilla, Margarita Sánchez-Beato, Luis Lombardía, Beatriz Domínguez-González, Diana Romero, Lina Odqvist, Pablo García-Sanz, Magdalena B. Wozniak, Guido Kurz, Carmen Blanco-Aparicio, Manuela Mollejo, F. Javier Alves, Javier Menárguez, Fernando González-Palacios, José Luis Rodríguez-Peralto, Pablo L. Ortiz-Romero, Juan F. García, James R. Bischoff, and Miguel A. Piris*

**Chronic Lymphocytic Leukemia**

65

**Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia**

*Emmanuelle Bouvet, Cécile Borel, Lucie Obéric, Gisèle Compaci, Bruno Cazin, Anne-Sophie Michallet, Guy Laurent, and Loic Ysebaert*

**Multiple Myeloma**

71

**Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data**

*Sarah Waheed, Alan Mitchell, Saad Usmani, Joshua Epstein, Shmuel Yaccoby, Bijay Nair, Rudy van Hemert, Edgardo Angtuaco, Tracy Brown, Twyla Bartel, James McDonald, Elias Anaissie, Frits van Rhee, John Crowley, and Bart Barlogie*

79

**Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry**

*Roberto J. Pessoa de Magalhães, María-Belén Vidriales, Bruno Paiva, Carlos Fernandez-Gimenez, Ramón García-Sanz, María-Victoria Mateos, Norma C. Gutierrez, Quentin Lecrevisse, Juan F Blanco, Jose Hernández, Natalia de las Heras, Joaquin Martínez-Lopez, Monica Roig, Elaine Sobral Costa, Enrique M. Ocio, Martín Perez-Andres, Angelo Maiolino, Marcio Nucci, Javier De La Rubia, Juan-Jose Lahuerta, Jesús F. San-Miguel, and Alberto Orfao on behalf the Spanish Myeloma Group (GEM) and Grupo Castellano-Leones de Gammapiatas Monoclonales, cooperative study groups*

87

**Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials**

*Antonio Palumbo, Anders Waage, Cyrille Hulin, Meral Bekzac, Sonja Zwegman, Francesca Gay, Peter Gimsing, Xavier Leleu, Pierre Wijermans, Gülsan Sucak, Sara Pezzatti, Gunnar Juliusson, Brigitte Pégourié, Martijn Schaafsma, Monica Galli, Ingemar Turesson, Brigitte Kolb, Bronno van der Holt, Ileana Baldi, Jürgen Rolke, Giovannino Ciccone, Marc Wetterwald, Henk Lokhorst, Mario Boccadoro, Philippe Rodon, and Pieter Sonneveld*

**Chronic myeloid leukemia**

95

**Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis**

*Ronit Gurion, Anat Gafter-Gvili, Liat Vidal, Avi Leader, Ron Ram, Adi Shacham-Abulafia, Mical Paul, Isaac Ben-Bassat, Ofer Shpilberg, and Pia Raanani*

**Chronic Myeloproliferative Disorders**

103

**Ponatinib as targeted therapy for *FGFR1* fusions associated with the 8p11 myeloproliferative syndrome**

*Andrew Chase, Catherine Bryant, Joannah Score, and Nicholas C.P. Cross*

**Myelodysplastic Syndromes**

107

**Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia**

*Sarah Abu Kar, Anna Jankowska, Hideki Makishima, Valeria Visconte, Andres Jerez, Yuka Sugimoto, Hideki Muramatsu, Fabiola Traina, Manuel Afable, Kathryn Guinta, Ramon V. Tiu, Bartłomiej Przychodzen, Hirotoshi Sakaguchi, Seiji Kojima, Mikkael A. Sekeres, Alan F. List, Michael A. McDevitt, and Jaroslaw P. Maciejewski*

**Acute Myeloid Leukemia**

114

**Retrospective comparison of clofarabine versus fludarabine in combination with high dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia**

*Pamela S. Becker, Hagop M. Kantarjian, Frederick R. Appelbaum, Barry Storer, Sherry Pierce, Jianqin Shan, Stephan Faderl, and Elihu H. Estey*

119

**Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia**

*Mikkael A. Sekeres, Jeffrey E. Lancet, Brent L. Wood, Laurie E. Grove, Larissa Sandalic, Eric L. Sievers, and Joseph G. Jurcic*

**Thalassemia Syndromes**

129

**Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine**

*Robert W. Grady, Renzo Galanello, Rachel E. Randolph, Dorothy A. Kleinert, Carlo Dessi, and Patricia J. Giardina*



Official Organ of the  
European Hematology Association

## Amyloidosis

- 136** **A prospective study of nutritional status in immunoglobulin light chain amyloidosis**  
*Prayman T. Sattianayagam, Thirusa Lane, Zoe Fox Aviva Petrie, Simon D.J. Gibbs, Jennifer H. Pinney, Signe S. Risom, Dorota M. Rowczenio, Ashutosh D. Wechalekar, Helen J. Lachmann, Janet A. Gilbertson, Philip N. Hawkins, and Julian D. Gillmore*
- 141** **Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience**  
*Andrew J. Cowan, Martha Skinner, David C. Seldin, John L. Berk, David R. Lichtenstein, Carl J. O'Hara, Gheorge Doros, and Vaishali Santhorawala*

## Hemostasis

- 147** **A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy**  
*Alessandra Casonato, Viviana Daidone, Giovanni Barbon, Elena Pontara, Irene Di Pasquale, Lisa Gallinaro, Letizia Marullo, and Giorgio Bertorelle*
- 153** **Murine tissue factor coagulant activity is critically dependent on the presence of an intact allosteric disulfide**  
*Lisa G. van den Hengel, Susanne Osanto, Pieter H. Reitsma, and Henri H. Versteeg*

## Letters to the editor

Letters are available online only at  
[www.haematologica.org/content/98/1.toc](http://www.haematologica.org/content/98/1.toc)

- e1** **Treating childhood acute lymphoblastic leukemia in Malawi**  
*George Chagaluka, Peter Carey, Kondwani Banda, Claire Schwab, Lucy Chilton, Ed Schwalbe, Roderick Skinner, Trijn Israels, Anthony Moorman, Elizabeth Molyneux, and Simon Bailey*  
<http://www.haematologica.org/content/98/1/e1>
- e4**  **$\beta$  thalassemia major due to acquired uniparental disomy in a previously healthy adolescent**  
*Celeste Bento, Tabita M. Maia, Jelena D. Milosevic, Isabel M. Carreira, Robert Kralovics, and M. Leticia Ribeiro*  
<http://www.haematologica.org/content/98/1/e4>

**e7** **HBB loss of heterozygosity in the hemopoietic lineage gives rise to an unusual sickle-cell trait phenotype**  
*Philippe Joly, Caroline Schluth-Bolard, Philippe Lacan, Claire Barro, Serge Pissard, Audrey Labalme, Damien Sanlaville, and Catherine Badens*  
<http://www.haematologica.org/content/98/1/e7>

**e9** **Hemoglobin sickle cell disease in Brazil**  
*Ana Carolina Cabañas-Pedro, Josefina A. P. Braga, Roberta F Camilo-Araújo, Ana I. M. Silva, Perla Vicari, and Maria Figueiredo*  
<http://www.haematologica.org/content/98/1/e9>

**e10** **Reply to "Response to "CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-1114**  
*Teresa Paíno, Bruno Paiva, and Jesús F. San Miguel*  
<http://www.haematologica.org/content/98/1/e10>

**e12** **Response to "CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-1114**  
*Marlies E.H.M. Van Hoef*  
<http://www.haematologica.org/content/98/1/e12>

## Continuing Medical Education

The effect of Thymoglobulin® on CD4<sup>+</sup> T cells post-transplantation

Combined use of deferasirox and deferoxamine

Standard and novel imaging methods for multiple myeloma

Ponatinib as targeted therapy for the 8p11 myeloproliferative syndrome